Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD
SZSE:300534.SZ
9.22 (CNY) • At close October 26, 2023
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 1,080.05 | 413.247 | 287.813 | 254.9 | 239.003 | 203.166 | 269.587 | 269.681 | 277.361 | 301.575 | 274.89 | 212.676 | 133.366 |
| Kosten van de omzet
| 386.229 | 249.524 | 195.421 | 171.8 | 148.539 | 116.765 | 181.463 | 171.915 | 169.408 | 200.778 | 202.367 | 161.604 | 101.626 |
| Brutowinst
| 693.821 | 163.723 | 92.392 | 83.1 | 90.464 | 86.401 | 88.124 | 97.766 | 107.953 | 100.797 | 72.523 | 51.073 | 31.74 |
| Brutowinstmarge
| 0.642 | 0.396 | 0.321 | 0.326 | 0.379 | 0.425 | 0.327 | 0.363 | 0.389 | 0.334 | 0.264 | 0.24 | 0.238 |
| Onderzoek- en ontwikkelingskosten
| 30.173 | 9.374 | 6.697 | 5.974 | 7.412 | 6.732 | 6.136 | 6.356 | 10.19 | 9.809 | 8.11 | 0 | 0 |
| Algemene en administratieve kosten
| 16.607 | 8.828 | 4.726 | 2.842 | 2.818 | 3.457 | 3.774 | 2.296 | 2.193 | 1.436 | 3.431 | 12.36 | 10.567 |
| Verkoop- en marketingkosten
| 508.026 | 91.703 | 67.188 | 52.688 | 45.61 | 47.263 | 46.567 | 25.753 | 12.883 | 15.499 | 10.892 | 8.957 | 6.515 |
| Verkoop-, algemene en administratieve kosten
| 524.633 | 100.531 | 71.915 | 55.53 | 48.428 | 50.72 | 50.34 | 28.049 | 15.076 | 16.935 | 14.323 | 21.317 | 17.082 |
| Overige kosten
| 1.82 | 5.467 | 4.634 | 1.573 | 0.501 | -0.008 | 0.036 | 4.621 | 2.145 | 3.076 | 2.537 | 1.835 | 2.875 |
| Bedrijfskosten
| 592.503 | 133.83 | 97.539 | 78.242 | 67.151 | 71.466 | 69.473 | 47.843 | 35.142 | 34.967 | 29.739 | 22.53 | 17.976 |
| Bedrijfsresultaat
| 95.2 | 26.733 | -9.383 | 2.245 | 19.533 | 13.524 | 18.079 | 50.112 | 69.818 | 68.003 | 45.696 | 27.898 | 13.557 |
| Bedrijfsresultaat ratio
| 0.088 | 0.065 | -0.033 | 0.009 | 0.082 | 0.067 | 0.067 | 0.186 | 0.252 | 0.225 | 0.166 | 0.131 | 0.102 |
| Totaal overige inkomsten en kosten netto
| -4.299 | 5.467 | 4.634 | 1.573 | 0.501 | -0.008 | 0.036 | 4.621 | 2.145 | 3.076 | 2.476 | 1.835 | 2.875 |
| Inkomen voor belasting
| 97.02 | 32.2 | -4.748 | 3.818 | 20.033 | 13.515 | 18.115 | 54.733 | 71.963 | 71.078 | 48.173 | 29.733 | 16.432 |
| Inkomen voor belasting ratio
| 0.09 | 0.078 | -0.016 | 0.015 | 0.084 | 0.067 | 0.067 | 0.203 | 0.259 | 0.236 | 0.175 | 0.14 | 0.123 |
| Belastingkosten
| 13.168 | 1.904 | 1.55 | 0.536 | 4.669 | 1.238 | 1.003 | 7.481 | 11.286 | 10.654 | 7.261 | 4.651 | 2.624 |
| Nettowinst
| 61.648 | 25.826 | -9.106 | 1.831 | 12.778 | 12.278 | 17.112 | 47.252 | 60.677 | 60.424 | 40.912 | 25.256 | 13.897 |
| Nettowinstmarge
| 0.057 | 0.062 | -0.032 | 0.007 | 0.053 | 0.06 | 0.063 | 0.175 | 0.219 | 0.2 | 0.149 | 0.119 | 0.104 |
| WPA (Winst Per Aandeel)
| 0.2 | 0.085 | -0.03 | 0.006 | 0.042 | 0.041 | 0.056 | 0.19 | 0.27 | 0.27 | 0.19 | 0.2 | 0.17 |
| Verwaterde WPA
| 0.2 | 0.085 | -0.03 | 0.006 | 0.042 | 0.041 | 0.056 | 0.19 | 0.27 | 0.27 | 0.19 | 0.2 | 0.17 |
| EBITDA
| 140.098 | 58.567 | 24.284 | 27.933 | 44.641 | 34.26 | 36.423 | 64.489 | 79.618 | 74.364 | 51.699 | 29.518 | 13.186 |
| EBITDA ratio
| 0.13 | 0.142 | 0.084 | 0.11 | 0.187 | 0.169 | 0.135 | 0.239 | 0.287 | 0.247 | 0.188 | 0.139 | 0.099 |